Navigation Links
Life Technologies Expands Line of High-Performance qPCR Instruments
Date:7/24/2013

CARLSBAD, Calif., July 24, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announces further expansion of its qPCR line of instruments with the introduction of two platforms: the QuantStudio™ 7 Flex Real-Time PCR and the QuantStudio™ 6 Flex Real-Time PCR systems. Each provides varying degrees of flexibility designed to match customers' performance and budget needs.

"The launch of these systems provides researchers with much needed application and throughput flexibility with a single instrument," said Chris Linthwaite, President of Genetic Analysis for Life Technologies. "Combined with our recently launched QuantStudio™ 3D Digital PCR System and 510(k)-cleared QuantStudio Dx Real-Time PCR Instrument, this product line now offers flexible solutions across the continuum of basic research to clinical diagnostics."

The QuantStudio™ 7 Flex Real-Time PCR System provides superior flexibility with four interchangeable blocks for experiments requiring either 96-well standard, 96-well fast, 384-well plates or a TaqMan® Array Card (TAC). Throughput is pushed even further with the system's automation capabilities. The new instrument is ideal for maximum multiplexing applications with support for six dyes and 21 filter capabilities.

The QuantStudio™ 6 Flex Real-Time PCR System is the entry-level platform that is competitively priced to enable customers to buy into the product line's high performance and flexibility. It is designed for use with three interchangeable blocks (96-well standard, 96-well fast, or 384-well plates) to fit mid-level throughput needs. As performance requirements increase with larger studies, the instrument can also be upgraded to a QuantStudio™ 7 Flex Real-Time PCR System with the purchase of a kit. 

qPCR has long been the workhorse technology used by researchers around the world to detect and decipher genetic variation underlying biological processes, agricultural diversity and human disease. Over 25,000 publications demonstrate the utility and performance of Applied Biosystems® qPCR instruments in gene expression, genotyping, micro RNA, copy number variation and protein analysis experiments.

The new platforms mark the fourth and fifth QuantStudio™ systems introduced by Life Technologies within the last year. Life Technologies first launched the line of instruments with the QuantStudio 12k Flex Real-Time PCR System in 2012.  The QuantStudio™ Dx Real-Time PCR Instrument launched in Europe later that year and received FDA clearance for use with Quidel's Clostridium difficile assay in March 2013. Most recently, the company began shipments of the QuantStudio™ 3D Digital PCR System in June.

"The tremendous pace of these new product introductions demonstrates Life Technologies commitment to developing truly innovative platforms designed to support the world's leading scientific work," Linthwaite said. "The QuantStudio 3D instrument sales have already far surpassed our global projections, signifying the value researchers attribute to these new products."

All systems referred to with exception to the QuantStudio™ Dx Real-Time PCR Instrument are for research use only; not intended for diagnostic purposes.

About Life Technologies 
Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Mauricio Minotta
760-929-2456
Mauricio.minotta@lifetech.com

 


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
3. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
4. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
5. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
6. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
7. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
8. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
9. MedClean Technologies Announces 2011 Results
10. Patient Safety Technologies Reports First Quarter 2012 Results
11. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce ... a longtime supporter of the event. , "We are pleased that KLS Martin is ... Havlik, 2017 ACPA President. "KLS Martin has a long track record of support of ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
(Date:2/23/2017)... York (PRWEB) , ... February 23, 2017 , ... Curemark, ... the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now ... clinical sites already enrolling children across the United States. , “There are currently ...
Breaking Medicine News(10 mins):